Sinovac Biotech has entered a partnership with researchers at the University of Hong Kong Clinical Trials Centre (HKU-CTC) and Gleneagles Hospital Hong Kong (GHK) in China to commence a clinical trial of an Omicron-specific Covid-19 inactivated vaccine for usage as a booster in the region.
The kick-off ceremony for commencing the trial was organised at GHK.
This trial will evaluate the safety and immunogenicity of the Sinovac vaccine as a booster in healthy adult participants to obtain scientific data for vaccination strategy in the future.
HKU-CTC’s medical research team is leading the trial in partnership with GHK.
Nearly 300 subjects of the age 18 years and above who received two or three doses of inactivated or mRNA Covid-19 vaccine will be recruited in the trial.
In December last year, Sinovac obtained the Omicron variant sample and subsequently progressed the research and development of its inactivated Covid-19 vaccine with Omicron specific strain.
According to preclinical research, the vaccine was found to safe and effective in animals.
In April this year, the HKU GHK Institutional Review Board (IRB) and the Pharmacy and Poisons Board of Hong Kong granted approval to begin the clinical trial of Omicron strain booster to improve people’s immunity against the new strain of the SARS-CoV-2 virus in Hong Kong.
Sinovac Biotech International Business Development director Cheryl Law said: “It is of great significance to cooperate with Professor Hung, HKU-CTC and Gleneagles to carry out the clinical trial of the Covid-19 inactivated vaccine as a booster shot against the Omicron strain.
“We hope to find a solution for Hong Kong and the globe to fight against the new viruses with the results of this trial.”
In June this year, Sinovac obtained the World Health Organization prequalification for its Poliomyelitis Vaccine (Vero Cell, Inactivated Sabin strains).